C-C Chemokine Receptor Type 4 - Pipeline Review, H2 2020

Summary:

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report C-C Chemokine Receptor Type 4 - Pipeline Review, H2 2020, outlays comprehensive information on the C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - C-C chemokine receptor type 4 is a protein encoded by the CCR4 gene. CCR4 is expressed on Th2 T lymphocytes and is up-regulated by T cell receptor activation. This receptor also plays an important role in trafficking of dendritic cells. The CC chemokines CCL3, CCL5, CCL17 and CCL22 signal through this receptor. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 5 and 1 respectively. Similarly, the universities portfolio in Phase I stages comprises 1 molecules, respectively.

Report covers products from therapy areas Oncology, Dermatology, Ear Nose Throat Disorders, Gastrointestinal, Immunology, Ophthalmology, Respiratory and Undisclosed which include indications Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Non-Hodgkin Lymphoma, Solid Tumor, Allergic Asthma, Allergic Conjunctivitis, Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Cervical Cancer, Chronic Urticaria Or Hives, Colon Tumor, Eosinophilic Esophagitis, Esophageal Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Liver Cancer, Melanoma, Nasopharyngeal Cancer, Non-Small Cell Lung Cancer, Pancreatic Tumor, Renal Cell Carcinoma, Rhinosinusitis, T-Cell Lymphomas, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Triple-Negative Breast Cancer (TNBC) and Unspecified.

Furthermore, this report also reviews key players involved in C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

• The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)
• The report reviews C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics and enlists all their major and minor projects
• The report assesses C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics

Reasons to Buy:

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

• Introduction
• Global Markets Direct Report Coverage
• C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Overview
• C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Therapeutics Development
• Products under Development by Stage of Development
• Products under Development by Therapy Area
• Products under Development by Indication
• Products under Development by Companies
• Products under Development by Universities/Institutes
• C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Therapeutics Assessment
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Companies Involved in Therapeutics Development
• Affitech A/S
• ChemoCentryx Inc
• CohBar Inc
• Eight Plus One Pharmaceutical Co Ltd
• Lassogen Inc
• RAPT Therapeutics Inc
• Tizona Therapeutics Inc
• C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Drug Profiles
• AT-008 - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• BJY-809 - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• CCX-6239 - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• FLX-475 - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• Gene Therapy to Target CD30 and CCR4 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• LAS-20X - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• Monoclonal Antibody to Target CCR4 for Oncology - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• Peptides to Inhibit CXCR4 for Melanoma and Orphan Diseases - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• RPT-193 - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Dormant Products
• C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Discontinued Products
• C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Product Development Milestones
• Featured News & Press Releases
• Appendix
• Methodology
• Coverage
• Secondary Research
• Primary Research
• Expert Panel Validation
• Contact Us
• Disclaimer

List of Tables

List of Tables

• Number of Products under Development by Stage of Development, H2 2020
• Number of Products under Development by Therapy Areas, H2 2020
• Number of Products under Development by Indications, H2 2020
• Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
• Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020
• Number of Products under Development by Companies, H2 2020
• Products under Development by Companies, H2 2020
• Products under Development by Companies, H2 2020 (Contd..1), H2 2020
• Products under Development by Companies, H2 2020 (Contd..2), H2 2020
• Products under Development by Companies, H2 2020 (Contd..3), H2 2020
• Number of Products under Investigation by Universities/Institutes, H2 2020
• Products under Investigation by Universities/Institutes, H2 2020
• Number of Products by Stage and Mechanism of Actions, H2 2020
• Number of Products by Stage and Route of Administration, H2 2020
• Number of Products by Stage and Molecule Type, H2 2020
• Pipeline by Actavalon Inc, H2 2020
• Pipeline by Active Biotech AB, H2 2020
• Pipeline by Ampio Pharmaceuticals Inc, H2 2020
• Pipeline by AnTolRx Inc, H2 2020
• Pipeline by Bayer AG, H2 2020
• Pipeline by Dermavant Sciences Inc, H2 2020
• Pipeline by Hercules Pharmaceuticals BV, H2 2020
• Pipeline by Hutchison MediPharma Ltd, H2 2020
• Pipeline by Ikena Oncology Inc, H2 2020
• Pipeline by JAGUAHR Therapeutics Pte Ltd, H2 2020
• Pipeline by Magenta Therapeutics Inc, H2 2020
• Pipeline by Pfizer Inc, H2 2020
• Pipeline by Phenex Pharmaceuticals AG, H2 2020
• Pipeline by Shenogen Pharma Group Ltd, H2 2020
• Pipeline by Sol-Gel Technologies Ltd, H2 2020
• Pipeline by Welichem Biotech Inc, H2 2020
• Dormant Products, H2 2020
• Dormant Products, H2 2020 (Contd..1), H2 2020
• Discontinued Products, H2 2020

List of Figures

List of Figures

• Number of Products under Development by Stage of Development, H2 2020
• Number of Products under Development by Therapy Areas, H2 2020
• Number of Products under Development by Top 10 Indications, H2 2020
• Number of Products by Stage and Mechanism of Actions, H2 2020
• Number of Products by Routes of Administration, H2 2020
• Number of Products by Stage and Routes of Administration, H2 2020
• Number of Products by Molecule Types, H2 2020
• Number of Products by Stage and Molecule Types, H2 2020